|
|
||||||
Journal of Clinical Oncology, Vol 26, No 3 (January 20), 2008: pp. 392-398 © 2008 American Society of Clinical Oncology. DOI: 10.1200/JCO.2007.13.3033 Effect of Breast Cancer Radiotherapy and Cigarette Smoking on Risk of Second Primary Lung Cancer
From the Departments of Epidemiology and Biostatistics, Mailman School of Public Health; Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University; and the Division of Medical Oncology, New York Presbyterian Hospital, New York, NY Corresponding author: Alfred I. Neugut, MD, PhD, Division of Medical Oncology, Columbia University Medical Center, 722 W 168th St, MSPH 725, New York, NY 10032; e-mail: ain1{at}columbia.edu Purpose: Prior studies have found that postmastectomy radiotherapy (PMRT) for breast cancer (BC) increases the risk of lung cancer (LC). We explored the joint effects of cigarette smoking and PMRT on LC risk.
Methods: We conducted a population-based nested case-control study among women registered in the Connecticut Tumor Registry diagnosed with nonmetastatic BC between January 1, 1965 and December 31, 1989. Patient cases developed a LC Results: Among 113 second primary LC patient cases and 364 controls, compared with nonsmoking women who did not receive PMRT, nonsmoking women who received PMRT had no higher risk of LC; adjusted odds ratios were 5.9 (95% CI, 2.7 to 12.8) for ever-smokers who did not receive PMRT and 18.9 (95% CI, 7.9 to 45.4) for ever-smokers who received PMRT. Adjusted odds ratios for the joint effects of smoking and PMRT were 10.5 (95% CI, 2.9 to 37.8) for the contralateral lung and 37.6 (95% CI, 10.2 to 139.0) for the ipsilateral lung. Smoking and PMRT were associated with increased risk for all histologic types of LC. Conclusion: PMRT after a diagnosis of BC sharply increased the risk of second primary LC, especially in the ipsilateral lung, among ever-smokers. Clinicians should consider including smoking history in their discussions with patients about the risks and benefits of PMRT. Supported by a supplement to National Cancer Institute (NCI) Grant No. P30 CA13696 and in part by a K07 award from NCI (Grant No. CA95597; to D.L.H.). Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. This article has been cited by other articles:
|
||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|